) recently announced that it has launched its attention deficit
hyperactivity disorder (ADHD) treatment, Quillivant XR
(methylphenidate hydrochloride) in the US.
Being the first once-daily liquid methylphenidate to be
approved in the US for ADHD, Quillivant XR provides ADHD patients
with an alternative treatment option. The ADHD market currently
has players like
Johnson & Johnson
) among others.
Quillivant XR, which was approved by the FDA in Sep 2012 for
use in patients 6 years and above, became a part of Pfizer's
portfolio following the company's Nov 2012 acquisition of
privately held, specialty pharma company NextWave
Pfizer decided to acquire NextWave under an option and merger
agreement with the company. At the time of announcing its
intention to acquire NextWave, Pfizer had said that it would make
a payment of $255 million to NextWave's shareholders on the
closing of the transaction. Moreover, NextWave's shareholders
could receive additional payments of up to $425 million on the
achievement of certain sales milestones.
This acquisition is in line with Pfizer's goal of expanding
its Established Products US brands business. Pfizer has been
looking to offset the impact of generic competition by bringing
new products to market. The company has been focusing on the
development of treatments in the fields of oncology, cardiology,
metabolic disorders, neuroscience, immunology, inflammation and
We currently have a Neutral recommendation on Pfizer, which
carries a Zacks Rank #3 (Hold). We expect near-term earnings at
Pfizer to be driven by cost cutting efforts and share
repurchases. Longer-term growth will be dependent on the success
of drug development.
While Shire is also a Zacks Rank #3 stock (Hold), Johnson
& Johnson is a Zacks Rank #2 (Buy) stock.
JOHNSON & JOHNS (JNJ): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.